At present, the company's annual sales income is nearly 700 million yuan, and profits and taxes are over 100 million yuan. It has the production capacity of producing more than 7 dosage forms 100 varieties of drugs such as infusion, tablets, capsules, oral liquid and lotion, and its production scale, technical level and brand influence rank among the top in the same industry in China. Leap into the top 100 domestic pharmaceutical enterprises. In June, 2007, the company joined hands with Xi Anlijun and successfully listed on the main board of Hong Kong. In the past 60 years, the four medicines have developed from scratch, from weak to strong, especially in the 30 years of reform and opening up, China's pharmaceutical industry has undergone tremendous changes. With the reform and innovation of enterprises, Shijiazhuang Four Medicines has experienced a gradual process of exploration, learning and independent innovation, and entered a new period of leap-forward development.
At the beginning of the reform and opening up, the production capacity of the enterprise was only four production lines, and now it has developed into 15 production lines for infusion, tablets, capsules, granules and oral liquid. Its leading product, large infusion production capacity and technical quality level, is in a leading position in China. From the initial low-level and low-level production mode, it has developed into a comprehensive large-scale enterprise in manufacturing, research and development, management, circulation and other fields.
In the early days of reform and opening up, the output value of enterprises was only more than 5 million yuan, and reached more than 400 million yuan in 2007; Sales revenue increased from more than 5 million yuan at the beginning to nearly 700 million yuan in 2007. In the early days of reform and opening up, profits and taxes were only 1 1 10,000 yuan. By 2007, the enterprise will realize profit and tax10.50 billion yuan. In the 30 years of reform and opening up, the total investment in scientific research and innovation of enterprises has exceeded 300 million yuan. In recent years, more than 20 new product approval numbers have been obtained every year. These scientific and technological achievements have laid a solid foundation for extending the popularity and brand influence of the four drugs. At present, 40% of the sales revenue of Shijiazhuang Four Drugs depends on new product sales, and 60% comes from high value-added products.
Product development and technical transformation have produced great benefits, created big brands, and established the position of Shi Si medicine as a leading enterprise in the domestic infusion industry. At present, the infusion production of enterprises covers various packaging forms of infusion products such as glass bottles, PP plastic bottles, non-PVC multilayer * * * extruded film soft bags. With advanced production technology and reliable product quality, the products of Shijiazhuang Four Medicines have gone abroad and sold to many countries and regions such as Russia.
After gaining a firm foothold in the main product infusion, the four drugs turned their attention to the Chinese medicine industry with huge market potential. While optimizing the quality of anti-aging fist products, a number of differentiated and characteristic Chinese medicine products such as He Shan oral liquid, Yinhuang capsule and Jin Lianhua oral liquid stand out. Since the beginning of the new century, Four Medicines has boldly adopted new technologies and equipment to promote the upgrading of pharmaceutical industry. The company introduced the most advanced automatic control equipment from Germany, Japan, Italy, South Korea and other countries. Through the strong link of automatic transmission system, the whole production process is closely linked from raw material input to product delivery, which truly realizes the overall automation and promotes the production capacity and efficiency of enterprises to a new height.
Since 2002, the company has invested nearly 400 million yuan to build an infusion high-tech industrial park project with international standards. At the beginning of planning this project, Siyao established the construction purpose of "high technology content, low energy consumption and no environmental pollution", and built a demonstration park for infusion production in domestic pharmaceutical industry with international standards. Nowadays, the domestic advanced PP plastic bottle infusion production line integrates washing, filling and sealing; 60 million bottles of multilayer * * * extrusion film infusion production line; A series of international infusion production facilities and processes, such as the logistics center with the largest storage capacity and the highest degree of intelligence in North China, are applied to infusion production. At present, the production technology and manufacturing level greatly exceed the existing infusion production line in China, and realize the integration with the world industry. As a pharmaceutical enterprise, product quality is not only related to the life of patients, but also related to the development destiny of enterprises. "Quality is the life of an enterprise", which is not just a slogan for the four medicine people with 60 years' experience, but deeply rooted in their hearts, integrated into the corporate culture and become the profound connotation of enterprise development.
In 1980s, at the beginning of the reform and opening up, Shijiazhuang No.4 Pharmaceutical Company put forward the quality concepts of "Good medicine cures diseases, bad medicine kills people" and "One bottle of infusion kills one person". In the 1990s, with the in-depth understanding of the concept of quality, the enterprise spirit of "loving the people with quality and taking quality as the foundation" was formed. Nowadays, the business philosophy of the four drugs has a new goal, with "making drugs well and benefiting mankind" as the highest pursuit of enterprise development.